SLS-009 is under clinical development by SELLAS Life Sciences Group and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SLS-009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SLS-009 overview

SLS-009 is under development for the treatment of refractory and relapsed acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), pediatric Ewing sarcoma and rhabdomyosarcoma, neuroendocrine prostate cancer, lymphoma, peripheral t-cell lymphomas (PTCL), extranodal marginal zone b-cell lymphoma (mucosa-associated lymphoid tissue or MALT-lymphoma), diffuse large b-cell lymphoma and Hodgkin lymphoma (B-cell hodgkin lymphoma). The drug candidate is administered through intravenous route. It acts by targeting cyclin-dependent kinase 9 (CDK9).

SELLAS Life Sciences Group overview

SELLAS Life Sciences Group (SELLAS) is a clinical biopharmaceutical company. Its products include GFH009, a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor and galinpepimut-S. Galinpepimut-S (GPS), a cancer immunotherapeutic drug that targets Wilms tumour 1, is in Phase 3 clinical studies for the treatment of acute myeloid leukaemia and in Phase 1/2 clinical trials for the treatment of ovarian cancer. The company collaborates with Memorial Sloan Kettering Cancer Center (MSKCC), National Cancer Institute (NCI) and The University of Texas M.D. Anderson Cancer Center (MDACC) for conducting clinical trials targeting multiple cancer indications. SELLAS is headquartered in New York City, New York, the US.

For a complete picture of SLS-009’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.